# CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride

> **NCT00968812** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 1452 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Glimepiride
- **DRUG:** Canagliflozin (JNJ-28431754)
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT00968812
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2011-12
- **Final completion:** 2013-01
- **Target enrollment:** 1452 (ACTUAL)
- **Last updated:** 2017-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00968812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00968812, "CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00968812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*